Let me start this by stating that I rarely post he

Let me start this by stating that I rarely post here and do not post at all on the other site anymore. Too much crap on both sites. I have been buying IPIX/CTIX for 4 years now and have not sold any shares that I have acquired. I originally entered for the Kevetrin potential but have been very happy with the Prurisol and Brilacidin development. I work in oral health and have treated oral mucositis cases over the years but none recently. If the case reaches severe, which they often do, then the patient is in such distress that complying with a study regimen which does not seem to be improving their condition and which involves "swishing" (the exact thing that is extremely painful for them) can be unbelievably difficult and is therefore more likely to be terminated. Obviously this could also apply to any patient in this Brilacidin study who was receiving the medication vs. placebo and not improving but one has to consider that if the medication were working as desired then FEWER WOULD DROP OUT due to the discomfort in the treatment group than in the placebo group. I believe that this is the primary reason for the higher than expected numbers for the placebo group (beyond the fact that the historical range for placebo can fluctuate) which make the response rate for the drug look lower than they could and I believe that those behind the scenes who may now be discussing options/deals/etc. well understand this and will be scrupulously analyzing the data for such possibility. Another thing to consider is that these patients often experience sudden changes in health status even if being helped with an isolated sequela such as OM. Such changes can certainly have an effect on their ability to continue daily activities and these changes would almost certainly be more impactful if the OM were worsening and causing general systemic issues. I believe that Drano has it right in post 39995.

As to formulation for Brilacidin delivery that has been discussed, in oral health often we use a fluconasol vaginal troche (obviously not designed for the oral cavity) for treating oral fungal infections BECAUSE it increases exposure to the oral cavity tissues over that received by liquid fluconasol (swish and swallow). It's not rocket science and could probably be relatively easily accomplished by a partner.

All IPO but I have not sold a single share and expect good things soon.